e non-inferior in terms of vaccine efficacy against respiratory
uadrivalent VLP (QVLP) at 30µg dose per strain was found to
mmunogenic in humans34–37. A plant-derived recombinant
n virus-like particles (VLPs) have been shown to be safe and
Vaccinescontainingplant-derivedrHAeitherinsolubleformor